14-3-3ζ Cooperates with ErbB2 to Promote Ductal Carcinoma In Situ Progression to Invasive Breast Cancer by Inducing Epithelial-Mesenchymal Transition

Andrechek, 2003, Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers, Cancer Res., 63, 4920 Bachman, 2005, Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter, Curr. Opin. Oncol., 17, 49, 10.1097/01.cco.0000143682.45316.ae Beavon, 2000, The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation, Eur. J. Cancer, 36, 1607, 10.1016/S0959-8049(00)00158-1 Burstein, 2004, Ductal carcinoma in situ of the breast, N. Engl. J. Med., 350, 1430, 10.1056/NEJMra031301 Comijn, 2001, The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion, Mol. Cell, 7, 1267, 10.1016/S1097-2765(01)00260-X Danes, 2008, 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling, Cancer Res., 68, 1760, 10.1158/0008-5472.CAN-07-3177 Debnath, 2003, Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures, Methods, 30, 256, 10.1016/S1046-2023(03)00032-X Di Guglielmo, 2003, Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover, Nat. Cell Biol., 5, 410, 10.1038/ncb975 Dumont, 2003, Targeting the TGF beta signaling network in human neoplasia, Cancer Cell, 3, 531, 10.1016/S1535-6108(03)00135-1 Elloul, 2005, Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma, Cancer, 103, 1631, 10.1002/cncr.20946 Feldner, 2002, Cancer cell motility—on the road from c-erbB-2 receptor steered signaling to actin reorganization, Exp. Cell Res., 272, 93, 10.1006/excr.2001.5385 Guarino, 2007, Epithelial-mesenchymal transition and tumour invasion, Int. J. Biochem. Cell Biol., 39, 2153, 10.1016/j.biocel.2007.07.011 Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 Hu, 2008, Regulation of in situ to invasive breast carcinoma transition, Cancer Cell, 13, 394, 10.1016/j.ccr.2008.03.007 Imamichi, 2007, Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer, Oncogene, 26, 2381, 10.1038/sj.onc.1210012 LeBron, 2006, Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3, EMBO J., 25, 1196, 10.1038/sj.emboj.7601032 Lin, 2004, Cytoplasmic PML function in TGF-beta signalling, Nature, 431, 205, 10.1038/nature02783 Liotta, 1991, Tumor invasion and metastasis: an imbalance of positive and negative regulation, Cancer Res., 51, 5054s Mani, 2008, The epithelial-mesenchymal transition generates cells with properties of stem cells, Cell, 133, 704, 10.1016/j.cell.2008.03.027 McGonigle, 2001, Conserved role for 14-3-3epsilon downstream of type I TGFbeta receptors, FEBS Lett., 490, 65, 10.1016/S0014-5793(01)02133-0 Melisi, 2008, LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis, Mol. Cancer Ther., 7, 829, 10.1158/1535-7163.MCT-07-0337 Muthuswamy, 2001, ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini, Nat. Cell Biol., 3, 785, 10.1038/ncb0901-785 Nofech-Mozes, 2005, Prognostic and predictive molecular markers in DCIS: a review, Adv. Anat. Pathol., 12, 256, 10.1097/01.pap.0000184177.65919.5e Peinado, 2004, Transcriptional regulation of cadherins during development and carcinogenesis, Int. J. Dev. Biol., 48, 365, 10.1387/ijdb.041794hp Perin, 1996, Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast, Eur. J. Cancer, 32A, 1148, 10.1016/0959-8049(96)00037-8 Provenzano, 2003, Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast, Eur. J. Cancer, 39, 622, 10.1016/S0959-8049(02)00666-4 Ringberg, 2001, Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics, Eur. J. Cancer, 37, 1514, 10.1016/S0959-8049(01)00165-4 Rizki, 2004, Homeostasis in the breast: it takes a village, Cancer Cell, 6, 1, 10.1016/j.ccr.2004.06.019 Rosivatz, 2002, Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer, Am. J. Pathol., 161, 1881, 10.1016/S0002-9440(10)64464-1 Seton-Rogers, 2004, Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells, Proc. Natl. Acad. Sci. USA, 101, 1257, 10.1073/pnas.0308090100 Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152 Strathdee, 2002, Epigenetic versus genetic alterations in the inactivation of E-cadherin, Semin. Cancer Biol., 12, 373, 10.1016/S1044-579X(02)00057-3 Tzivion, 2006, 14-3-3 proteins as potential oncogenes, Semin. Cancer Biol., 16, 203, 10.1016/j.semcancer.2006.03.004 Van de Putte, 2003, Mice lacking ZFHX1B, the gene that codes for Smad-interacting protein-1, reveal a role for multiple neural crest cell defects in the etiology of Hirschsprung disease-mental retardation syndrome, Am. J. Hum. Genet., 72, 465, 10.1086/346092 Weaver, 1997, Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies, J. Cell Biol., 137, 231, 10.1083/jcb.137.1.231 Wilker, 2004, 14-3-3 Proteins—a focus on cancer and human disease, J. Mol. Cell. Cardiol., 37, 633, 10.1016/j.yjmcc.2004.04.015 Yang, 2003, 14-3-3 sigma positively regulates p53 and suppresses tumor growth, Mol. Cell. Biol., 23, 7096, 10.1128/MCB.23.20.7096-7107.2003 Yang, 2002, Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects, J. Clin. Invest., 109, 1607, 10.1172/JCI200215333 Yingling, 2004, Development of TGF-beta signalling inhibitors for cancer therapy, Nat. Rev. Drug Discov., 3, 1011, 10.1038/nrd1580 Yu, 2000, Overexpression of ErbB2 in cancer and ErbB2-targeting strategies, Oncogene, 19, 6115, 10.1038/sj.onc.1203972 Zavadil, 2005, TGF-beta and epithelial-to-mesenchymal transitions, Oncogene, 24, 5764, 10.1038/sj.onc.1208927